PME-1 as a biomarker to predict and diagnose endometrial and breast cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition
AssigneeMedical Diagnostic Laboratories, LLC
InventorsLyndi M. Rice, Michelle Pusey
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer and triple negative breast cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
Claims5
A method of treating a human subject suffering from triple negative breast cancer and is in need of treatment, comprising the steps of:
- a) identifying a human subject having triple negative breast cancer and in need of treatment thereof;
- and
- b) administering to said human subject an effective amount of RNAi targeted against PME-1 selected from the group consisting of siRNA and shRNA, wherein said RNAi reduces the gene expression of PME-1 in said triple negative breast cancer and thereby inhibits tumor growth of said triple negative breast cancer, and
- wherein said RNAi having a target sequence selected from the group consisting of SEQ ID NO:
- 17, SEQ ID NO:
- 2 and SEQ ID NO:
- 3.
A method of treating a human subject suffering from triple negative breast cancer and is in need of treatment, comprising the steps of:
- a) identifying a human subject having triple negative breast cancer and in need of treatment thereof;
- and
- b) administering to said human subject an effective amount of RNAi targeted against PME-1 wherein said RNAi reduces the gene expression of PME-1 in said triple negative breast cancer and thereby inhibits tumor growth of said triple negative breast cancer, and
- wherein said RNAi having a target sequence selected from the group consisting of SEQ ID NO:
- 8 and SEQ ID NO:
- 9.
A method of inhibiting tumor growth of a triple negative breast cancer cell, comprising the step of exposing a triple negative breast cancer cell with RNAi selected from the group consisting of siRNA and shRNA targeted against PME-1, wherein said RNAi reduces PME-1 gene expression and thereby inhibits tumor growth of said triple negative breast cancer cell, and
- wherein said RNAi having a target sequence selected from the group consisting of SEQ ID NO:
- 17, SEQ ID NO:
- 2 and SEQ ID NO:
- 3.
A method of inhibiting tumor growth of a triple negative breast cancer cell, comprising the step of exposing a triple negative breast cancer cell with RNAi targeted against PME-1, wherein said RNAi reduces PME-1 gene expression and thereby inhibits tumor growth of said triple negative breast cancer cell, and
- wherein said RNAi having a target sequence selected from the group consisting of SEQ ID NO:
- 8 and SEQ ID NO:
- 9.
A composition comprising shRNA contained in an adenoviral expression vector operably linked to said shRNA and a pharmaceutical acceptable excipient, wherein said shRNA having a target sequence consisting of SEQ ID NO:
- 2 or SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.